Recent studies have demonstrated that the use of paramagnetic hepatobiliary contrast
agents in the acquisition of magnetic resonance images remarkably improves the
detection and differentiation of focal liver lesions, as compared with extracellular
contrast agents. Paramagnetic hepatobiliary contrast agents initially show the
perfusion of the lesions, as do extracellular agents, but delayed contrast-enhanced
images can demonstrate contrast uptake by functional hepatocytes, providing further
information for a better characterization of the lesions. Additionally, this
intrinsic characteristic increases the accuracy in the detection of hepatocellular
carcinomas and metastases, particularly the small-sized ones. Recently, a
hepatobiliary contrast agent called gadolinium ethoxybenzyl dimeglumine, that is
simply known as gadoxetic acid, was approved by the National Health Surveillance
Agency for use in humans. The authors present a literature review and a practical
approach of magnetic resonance imaging utilizing gadoxetic acid as contrast agent,
based on patients' images acquired during their initial experiment.